Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab and Quemliclustat with Chemotherapy in Pancreatic Adenocarcinoma
NCT05688215Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab and quemliclustat in pancreatic adenocarcinoma (PDAC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events (BPRC Cohort), Resection rate (BPRC Cohort) up to 2 years and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
zimberelimabquemliclustat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05688215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688215.